OverviewSuggest Edit

G1 is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of cancer. The Company focuses on cyclin-dependent kinases, or CDKs, a family of proteins that plays an important role in the growth and proliferation of cells, and represents a recently validated and promising class of targets for anti-cancer therapeutics.
TypePublic
Founded2008
HQUS
Websiteg1therapeutics.com

Latest Updates

Employees (est.) (Dec 2019)104(+24%)
Job Openings7
Revenue (FY, 2017)$0
Share Price (Sept 2020)$14.3 (-6%)
Cybersecurity ratingAMore

Key People/Management at G1 Therapeutics

Mark Velleca

Mark Velleca

CEO
Garry Nicholson

Garry Nicholson

Chair
Mark Avagliano

Mark Avagliano

Chief Business Officer
Seth Rudnick

Seth Rudnick

Director
Soma Gupta

Soma Gupta

Chief Commercial Officer
Jennifer Moses

Jennifer Moses

Chief Financial Officer
Show more

G1 Therapeutics Office Locations

G1 Therapeutics has an office in
Show all (1)

G1 Therapeutics Financials and Metrics

G1 Therapeutics Revenue

USD

Revenue (Q2, 2020)

2.1m

Net income (Q2, 2020)

(31.2m)

EBIT (Q2, 2020)

(30.8m)

Market capitalization (21-Sept-2020)

542.8m

Closing stock price (21-Sept-2020)

14.3

Cash (30-Jun-2020)

234.3m

EV

333.2m
G1 Therapeutics's current market capitalization is $542.8 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

522.0k

Revenue growth, %

(100%)

General and administrative expense

3.2m5.2m7.1m18.6m40.0m

R&D expense

12.7m25.2m53.9m70.7m89.0m
Quarterly
USDQ2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.1m

General and administrative expense

1.7m1.9m3.4m3.3m4.9m7.8m9.1m11.1m11.4m14.4m

R&D expense

13.7m14.1m17.3m18.4m15.9m18.1m23.5m22.9m20.4m18.5m

Operating expense total

15.4m15.9m20.7m21.7m20.8m25.9m32.6m34.0m31.8m33.0m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

47.3m103.8m369.3m269.2m

Prepaid Expenses

596.0k849.0k843.0k1.7m

Current Assets

47.9m104.7m370.1m271.0m

PP&E

311.0k510.0k1.1m3.5m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(20.3m)(30.3m)(60.1m)(85.3m)(122.4m)

Depreciation and Amortization

42.0k67.0k89.0k175.0k356.0k

Accounts Payable

1.7m3.4m6.3m(1.0m)248.0k

Cash From Operating Activities

(13.8m)(25.1m)(50.5m)(74.3m)(99.6m)
Quarterly
Show all financial metrics

G1 Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

G1 Therapeutics Online and Social Media Presence

Embed Graph

G1 Therapeutics News and Updates

G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer

- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration- Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust myelopreservation benefits- G1 launching expanded access program (EAP) for patients with small cell l…

G1 Therapeutics and Genor Biopharma Announce Exclusive License Agreement for Lerociclib in Asia-Pacific Region

- G1 to receive $6 million upfront payment, sales royalties and up to $40 million in future milestone payments- Genor to lead clinical development, regulatory submissions and commercialization of lerociclib in Asia-Pacific

G1 Therapeutics to Participate in BTIG Targeted Therapeutics Conference on February 24, 2020

RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Medical Officer Raj Malik, M.D., will participate in the “Breast Cancer – The Moving Landscape” panel discussion at the BTIG Targeted …

G1 Therapeutics Presents Updated Data from Phase 1b/2a Trial of Oral CDK4/6 Inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)

RESEARCH TRIANGLE PARK, N.C. and SAN ANTONIO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today reported additional data from the Phase 1b/2a clinical trial investigating its oral CDK4/6 inhibitor lerociclib in combination with fulvest…

G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019

-- Company to host investor and analyst event, webcast and conference call today at 12:45 p.m. ET -- RESEARCH TRIANGLE PARK, N.C. and BARCELONA, SPAIN, Sept. 29, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary results fr…

G1 Therapeutics Presents Updated Data at ESMO 2019 from Randomized Phase 2 Trial of Trilaciclib in Combination with Chemotherapy in Metastatic Triple-Negative Breast Cancer Demonstrating Significant Improvement in Overall Survival

-- Trial results published simultaneously in The Lancet Oncology -- -- Company also to present updated Phase 2 results demonstrating myelopreservation benefits in small cell lung cancer (SCLC) patients receiving trilaciclib and chemotherapy in combination with Tecentriq® --
Show more

G1 Therapeutics Blogs

G1 Therapeutics Announces License Agreement for Lerociclib

G1 Therapeutics Announces License Agreement for Lerociclib Content Import Wed, 07/22/2020 - 18:00 G1 Therapeutics Announces License Agreement for Lerociclib July 22, 2020 at 6:00 PM EDT This release is a backfill from a News Wire General …

Jack Bailey

Jack Bailey Michael.Fuccio… Tue, 07/14/2020 - 17:22 Member of the Audit Committee Member of the Nominating and Governance Committee Jack Bailey Mr. Bailey has nearly thirty years of commercial pharmaceutical experience and has an in-depth understanding of healthcare market dynami…

G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico

G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico Content Import Tue, 06/30/2020 - 16:10 G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small C…

G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital

G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital Content Import Mon, 06/01/2020 - 16:01 G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital June 1, 2020 at 4:01 PM EDT …

G1 Therapeutics to Present Data Showing Myelopreservation Benefits of Trilaciclib in Patients with Small Cell Lung Cancer at the ASCO20 Virtual Scientific Program

- Trilaciclib significantly reduced myelosuppression and need for related supportive care interventions for patients with small cell lung cancer (SCLC) receiving chemotherapy - New Drug Application (NDA) submission for trilaciclib in SCLC on track for completion in 2Q20 RESEARCH TRIANGLE PARK, N.C.

G1 Therapeutics Provides First Quarter 2020 Corporate and Financial Update

New Drug Application (NDA) submission for trilaciclib in small cell lung cancer on track for 2Q20 Rintodestrant combination trial with palbociclib expected to initiate in 2Q20 Management to host webcast and conference call today at 4:30 p.m. ET RESEARCH TRIANGLE PARK, N.C.
Show more

G1 Therapeutics Frequently Asked Questions

  • When was G1 Therapeutics founded?

    G1 Therapeutics was founded in 2008.

  • Who are G1 Therapeutics key executives?

    G1 Therapeutics's key executives are Mark Velleca, Garry Nicholson and Mark Avagliano.

  • How many employees does G1 Therapeutics have?

    G1 Therapeutics has 104 employees.

  • Who are G1 Therapeutics competitors?

    Competitors of G1 Therapeutics include 4SC, X4 Pharmaceuticals and Syndax Pharmaceuticals.

  • Where are G1 Therapeutics offices?

    G1 Therapeutics has an office in.

  • How many offices does G1 Therapeutics have?

    G1 Therapeutics has 1 office.